Insider Buying: DENTSPLY SIRONA (NASDAQ:XRAY) Director Buys 10,000 Shares of Stock

DENTSPLY SIRONA Inc. (NASDAQ:XRAY) Director Brian Mckeon purchased 10,000 shares of the business’s stock in a transaction dated Friday, June 12th. The stock was bought at an average cost of $10.12 per share, with a total value of $101,200.00. Following the completion of the acquisition, the director owned 10,000 shares of the company’s stock, valued at approximately $101,200. The trade was a ? increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link.

DENTSPLY SIRONA Price Performance

Shares of NASDAQ XRAY traded up $0.05 during trading on Monday, reaching $10.14. The company had a trading volume of 2,937,234 shares, compared to its average volume of 4,807,820. DENTSPLY SIRONA Inc. has a twelve month low of $9.40 and a twelve month high of $17.09. The stock has a market capitalization of $2.03 billion, a PE ratio of -3.22, a price-to-earnings-growth ratio of 1.20 and a beta of 0.89. The stock has a 50-day moving average price of $10.98 and a two-hundred day moving average price of $11.71. The company has a current ratio of 1.53, a quick ratio of 0.98 and a debt-to-equity ratio of 1.52.

DENTSPLY SIRONA (NASDAQ:XRAY) last released its quarterly earnings results on Tuesday, May 5th. The medical instruments supplier reported $0.27 earnings per share for the quarter, missing analysts’ consensus estimates of $0.28 by ($0.01). The company had revenue of $880.00 million during the quarter, compared to analyst estimates of $841.80 million. DENTSPLY SIRONA had a positive return on equity of 18.83% and a negative net margin of 17.06%.The business’s revenue was up .1% compared to the same quarter last year. During the same period last year, the firm earned $0.43 earnings per share. DENTSPLY SIRONA has set its FY 2026 guidance at 1.400-1.500 EPS. As a group, sell-side analysts predict that DENTSPLY SIRONA Inc. will post 1.42 earnings per share for the current year.

Institutional Investors Weigh In On DENTSPLY SIRONA

A number of institutional investors have recently added to or reduced their stakes in the company. Bank of America Corp DE grew its position in DENTSPLY SIRONA by 18.3% during the first quarter. Bank of America Corp DE now owns 2,432,457 shares of the medical instruments supplier’s stock valued at $28,217,000 after acquiring an additional 375,994 shares during the period. RBF Capital LLC grew its position in DENTSPLY SIRONA by 2.5% during the first quarter. RBF Capital LLC now owns 205,000 shares of the medical instruments supplier’s stock valued at $2,378,000 after acquiring an additional 5,000 shares during the period. Arkadios Wealth Advisors purchased a new stake in DENTSPLY SIRONA during the first quarter valued at about $870,000. California State Teachers Retirement System grew its position in DENTSPLY SIRONA by 24.0% during the first quarter. California State Teachers Retirement System now owns 232,031 shares of the medical instruments supplier’s stock valued at $2,692,000 after acquiring an additional 44,918 shares during the period. Finally, Royal Bank of Canada grew its position in DENTSPLY SIRONA by 137.7% during the first quarter. Royal Bank of Canada now owns 256,701 shares of the medical instruments supplier’s stock valued at $2,978,000 after acquiring an additional 148,702 shares during the period. Hedge funds and other institutional investors own 95.70% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities analysts recently commented on XRAY shares. Mizuho dropped their target price on DENTSPLY SIRONA from $16.00 to $14.00 and set a “neutral” rating for the company in a research note on Wednesday, May 6th. UBS Group dropped their target price on DENTSPLY SIRONA from $18.00 to $17.00 and set a “buy” rating for the company in a research note on Thursday, May 7th. Robert W. Baird upped their target price on DENTSPLY SIRONA from $12.00 to $14.00 and gave the company a “neutral” rating in a research note on Friday, February 27th. Barrington Research upped their target price on DENTSPLY SIRONA from $14.00 to $17.00 and gave the company an “outperform” rating in a research note on Monday, March 2nd. Finally, Weiss Ratings lowered DENTSPLY SIRONA from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Wednesday, May 6th. Three research analysts have rated the stock with a Buy rating, eight have assigned a Hold rating and three have assigned a Sell rating to the stock. Based on data from MarketBeat, DENTSPLY SIRONA has a consensus rating of “Hold” and a consensus target price of $13.55.

About DENTSPLY SIRONA

Dentsply Sirona Inc (NASDAQ: XRAY) is a leading global manufacturer of professional dental products and technologies. The company, formed through the merger of Dentsply International and Sirona Dental Systems in February 2016, brings together a long heritage of innovation in dental care. Headquartered in Charlotte, North Carolina, Dentsply Sirona develops and markets a comprehensive range of dental consumables, laboratory products, and advanced imaging and CAD/CAM systems.

The company’s product portfolio spans preventive, restorative, orthodontic, endodontic and surgical care.